Cheelcare Announces Grant of Stock Options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cheelcare (CHCRF) granted 485,000 incentive stock options to directors, employees and consultants, effective November 13, 2026, under its stock option plan.
The options are exercisable at $1.50 per common share until November 13, 2031. The 220,000 director options and 25,000 consultant options vest fully on the grant's first anniversary. Another 220,000 employee options and 20,000 consultant options vest 50% on each of the first two anniversaries. The grants are subject to plan terms and applicable TSX Venture Exchange policies, including exchange acceptance where required. Following the November 13 annual meeting, the board confirmed its existing committees and chairs would continue.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.485,000 stock options exercisable at $1.50 per common share until November 13, 2031 create potential dilution.
- Minor pointOption grants remain subject to TSX Venture Exchange acceptance where required.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Markham, Ontario--(Newsfile Corp. - November 16, 2026) - Cheelcare Inc. (TSXV: CHER) (OTC: CHCRF) ("Cheelcare" or the "Company"), a Canadian innovator in advanced mobility solutions, announces the grant of an aggregate of 485,000 incentive stock options (the "Options") to certain directors, officers, employees and consultants pursuant to the Company's stock option plan (the "Plan").
The Options were granted effective November 13, 2026 and are exercisable at
Of the Options granted, 220,000 were granted to directors and 25,000 were granted to a consultant, with these Options vesting in full on the first anniversary of the grant date. The remaining 240,000 Options, consisting of 220,000 granted to employees and 20,000 granted to a consultant, will vest as to
The Options are subject to the terms of the Company's stock option plan and the applicable policies of the TSX Venture Exchange, including acceptance by the TSX Venture Exchange, where required.
Board Committees
Following the Company's Annual General Meeting held on November 13, 2026, the Board of Directors confirmed the continuation of its existing board committees and their respective chairs. Trevor Treweeke will continue to serve as Chair of the Audit Committee, while Marc Kazimirski will continue as Chair of the Governance, Human Resources, Nominating and Compensation Committee. Roy Ellis will continue to serve as Chairman of the Board.
About Cheelcare Inc.
Cheelcare designs and manufactures innovative mobility solutions that empower independence for people with disabilities. From the Companion power assist devices to the groundbreaking Curio robotic complex-rehab power wheelchair, Cheelcare combines engineering excellence with human-centered design to improve quality of life. For more information, please visit: www.cheelcare.ca.
For further information, please contact:
Sofiya Kagan, Director of Marketing
Cheelcare Inc.
Tel: 1-888-948-2680 x 206
Email: skagan@cheelcare.com
Forward-Looking Information:
This news release may contain forward-looking statements. Forward-looking statements are based on current expectations and involve known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those expressed or implied. Such factors include, but are not limited to, general economic conditions, market demand, supply chain disruptions, and regulatory approvals. Any forward-looking statements are made as of the date of this news release, and the Company does not undertake to update any forward-looking statements except in accordance with applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/324320
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What are the exercise price and expiration date of Cheelcare's November 2026 stock options?
Cheelcare's 485,000 incentive stock options are exercisable at $1.50 per common share until November 13, 2031. The grants were effective November 13, 2026.
When do Cheelcare's November 2026 stock option grants vest?
The 220,000 director options and 25,000 consultant options vest fully on the first anniversary of the grant date. The remaining 240,000 options, comprising 220,000 employee options and 20,000 consultant options, vest 50% on the first anniversary and 50% on the second anniversary.